Day One Biopharmaceuticals, Inc.
Clinical trials sponsored by Day One Biopharmaceuticals, Inc., explained in plain language.
-
New drug XMT-1660 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New smart drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …
Phase: PHASE1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC